Free Trial
→ Do NOT Buy SpaceX – Do This Instead (From Stansberry Research) (Ad)tc pixel
NASDAQ:AXGN

AxoGen Q3 2026 Earnings Date & Estimates

AxoGen logo
$36.13 -0.05 (-0.14%)
Closing price 04:00 PM Eastern
Extended Trading
$36.15 +0.02 (+0.06%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

AxoGen is expected to report Q3 2026 earnings on Wednesday, November 4, 2026, before market opens. The conference call is scheduled for October 28, 2026 at 8:00 AM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call Date
Conference Call
8:00 AM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from AxoGen in Q3 2026

AxoGen is expected to post earnings of $0.13 per share on revenue of $73.18 million. In the same quarter a year earlier AxoGen reported $0.12 per share on revenue of $60.08 million. AxoGen last reported on July 29, 2026, posting $0.12 per share and missing the $0.1214 consensus estimate. AxoGen has beaten the consensus EPS estimate in 5 of its last 8 quarters.

Consensus Estimates

Consensus EPS
$0.13
Expected Revenue
$73.18 million
Prior-Year EPS
$0.12
Prior-Year Revenue
$60.08 million
Expected EPS Growth
+8.3%
Expected Revenue Growth
+21.8%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
$0.12 (Missed by -$0.0014)
Last Quarter Revenue
$69.73 million
EPS Beat Rate
5 of last 8 quarters

Prepare for the Q3 2026 Call

AxoGen Q3 2026 Earnings FAQ

AxoGen (NASDAQ:AXGN) is estimated to report Q3 2026 earnings on Wednesday, November 4, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

AxoGen's Q3 2026 earnings conference call is scheduled for Wednesday, October 28, 2026 at 8:00 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect AxoGen to post earnings of $0.13 per share for Q3 2026.

The consensus revenue estimate for AxoGen is $73.18 million for Q3 2026.

AxoGen Earnings Headlines

Axogen (AXGN) Stock Could Be 26% Undervalued On Cash Flow Grounds
October 9 at 6:37 PM  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/axogen-axgn-stock-could-26-180822766.html
Barclays initiates coverage of Axogen with overweight rating
October 7 at 6:10 PM  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/barclays-initiates-coverage-of-axogen-with-overweight-rating/ar-AA2dLR7K
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.tc pixel
October 9 at 1:00 AM  |  InvestorPlace (Ad)
Wells Fargo Sticks to Its Buy Rating for AxoGen (AXGN)
October 6 at 10:07 PM  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/AXGN/pressreleases/4951143/wells-fargo-sticks-to-its-buy-rating-for-axogen-axgn/
GE HealthCare Technologies (NASDAQ:GEHC) versus AxoGen (NASDAQ:AXGN) Head to Head Review
October 6 at 4:44 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31090972
AxoGen (NASDAQ:AXGN) Upgraded at Truist Financial
October 4, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31083850
See More AxoGen Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like AxoGen? Sign up for Earnings360's daily newsletter to receive timely earnings updates on AxoGen and other key companies, straight to your email.

About AxoGen

AxoGen (NASDAQ:AXGN) is a medical technology company focused on repairing and regenerating damaged peripheral nerves. The company develops and commercializes products for use by surgeons treating traumatic nerve injuries and other conditions in which nerve function has been compromised.

AxoGen’s product portfolio includes Avance Nerve Graft, a processed human nerve allograft designed to bridge gaps in damaged nerves without requiring tissue to be taken from another part of the patient’s body. Its offerings also include Axoguard Nerve Connector and Axoguard Nerve Protector products, which are designed to support nerve repair and protect nerves during healing, as well as other products for peripheral nerve reconstruction.

Founded in 2002, AxoGen is headquartered in Alachua, Florida. The company markets its products primarily to hospitals and specialty surgeons in the United States and also serves selected international markets through direct sales and distribution relationships. Its products are used across areas including upper- and lower-extremity reconstruction, plastic and reconstructive surgery, orthopedic surgery, and other procedures involving peripheral nerve repair.

View AxoGen Profile
Earnings Tools